10-Q: Walgreens Boots Alliance Reports Mixed Q3 Results Amidst Strategic Review

Walgreens Boots Alliance's Q3 results show a mixed performance with a significant goodwill impairment charge impacting overall profitability, while cost-saving initiatives and U.S. Healthcare improvements offer some positives.

Summary

• Walgreens Boots Alliance (WBA) reported a net loss of $5.631 billion for the nine months ended May 31, 2024, primarily due to a $12.4 billion goodwill impairment charge related to VillageMD.
• The company's Q3 net earnings attributable to WBA were $344 million, a significant increase compared to $118 million in the same period last year, but this was largely due to a prior year impairment.
• Adjusted net earnings for Q3 decreased by 36.6% to $545 million, and adjusted diluted earnings per share decreased by 36.6% to $0.63.
• Sales for Q3 increased by 2.6% to $36.351 billion, with U.S. Retail Pharmacy sales up 2.3% and International sales up 2.8%.
• The company is undergoing a strategic review, which includes a U.S. store optimization program, a U.S. Retail Pharmacy action plan, and a simplification of the U.S. Healthcare portfolio.
• WBA is on track to achieve its $4.5 billion cost savings target by the end of fiscal 2024 through its Transformational Cost Management Program.
• The company has closed 581 Boots stores in the UK and 673 stores in the U.S. as part of its optimization efforts.
• WBA has accrued a total of $6.6 billion in liabilities related to opioid-related claims and litigation settlements.
• The company's senior unsecured debt ratings were lowered to BBBby Standard and Poor's and Ba2 by Moody's, impacting its ability to issue commercial paper and potentially increasing borrowing costs.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant negatives such as the large goodwill impairment and debt rating downgrades, offset by some positives like cost savings and improved healthcare performance. The overall sentiment is cautiously negative due to the financial challenges and strategic uncertainties.

Positives

• The company's Q3 net earnings attributable to WBA increased to $344 million, up from $118 million in the same period last year.
• WBA is on track to achieve its $4.5 billion cost savings target by the end of fiscal 2024.
• U.S. Healthcare segment showed improved profitability compared to the previous year.
• Comparable pharmacy sales in the U.S. increased by 5.7% in Q3.
• International segment sales increased by 2.8% in Q3, with growth in both the Germany wholesale business and Boots UK.

Negatives

• Walgreens Boots Alliance reported a net loss of $5.631 billion for the nine months ended May 31, 2024, primarily due to a $12.4 billion goodwill impairment charge related to VillageMD.
• Adjusted net earnings for Q3 decreased by 36.6% to $545 million, and adjusted diluted earnings per share decreased by 36.6% to $0.63.
• U.S. retail sales decreased by 4.0% in Q3, reflecting a challenging retail environment.
• The company's senior unsecured debt ratings were lowered by both Standard and Poor's and Moody's.
• The company has a significant liability of $6.6 billion related to opioid-related claims and litigation settlements.

Risks

• The company faces risks related to opioid-related claims and litigation settlements, which have resulted in a $6.6 billion liability.
• Adverse global macroeconomic conditions, including inflation and high interest rates, could impact the company's operations and financial results.
• The company's credit ratings have been downgraded, which may increase borrowing costs and limit access to capital markets.
• The company's financial performance is dependent on the performance of its equity method investees, including Cencora, and its consolidated subsidiaries in the U.S. Healthcare segment.
• The company is undergoing a strategic review, which may lead to further changes in its business and strategy, creating uncertainty.
• The company's ability to generate cash flow may be adversely affected by adverse global macroeconomic conditions.

Future Outlook

The company is undergoing a strategic review and is analyzing opportunities that may impact future results, including a U.S. footprint optimization program, a U.S. Retail Pharmacy action plan, and a simplification of the U.S. Healthcare portfolio. The company continues to evaluate its overall portfolio of assets and investments and may take action in line with the company's strategic direction.

Management Comments

• The company believes it is currently on track to achieve the savings target of $4.5 billion by the end of fiscal 2024.
• The company is dependent on funding from its subsidiaries to pay dividends and meet its obligations.
• The company expects to fund its working capital needs, capital expenditures, expansion, acquisitions, dividend payments, stock repurchases and debt service obligations from liquidity sources including cash flow from operations, availability under existing credit facilities, working capital financing arrangements, debt offerings, sale of marketable securities, current cash, and monetization of investments and other assets.

Industry Context

The results reflect a challenging environment for retail pharmacies, with increased reimbursement pressure and a shift in consumer behavior. The company's strategic review and cost-cutting measures are in line with industry trends to optimize operations and improve profitability. The focus on healthcare services and digital channels also aligns with the broader industry shift towards integrated healthcare solutions.

Comparison to Industry Standards

• WBA's performance is mixed compared to its peers. While the company is making progress on cost savings, the significant goodwill impairment charge and the decline in adjusted earnings are concerning.
• CVS Health, a major competitor, has also been focusing on healthcare services and cost management, but has not reported a similar level of goodwill impairment.
• Other pharmacy chains like Rite Aid have faced financial difficulties, highlighting the challenges in the current market.
• WBA's international segment, particularly Boots UK, has shown some resilience, which is a positive sign compared to the struggles in the U.S. retail market.
• The company's debt rating downgrade is a negative signal compared to peers with stable or positive outlooks.

Management Changes

Corporate Governance

Legal Proceedings

• The company has accrued a total of $6.6 billion liability associated with the Multistate Settlement Agreement and other opioid-related claims and litigation settlements.
• The company is defending a number of claims, lawsuits and investigations that allege that the company's retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process.
• The company is involved in a commercial arbitration with Everly Health Solutions, with a final award of $988 million against the company, which the company is disputing.

Related Party Transactions

• The company has a long-term pharmaceutical distribution agreement with Cencora, with purchases totaling $18.181 billion for the three months ended May 31, 2024, and $54.296 billion for the nine months ended May 31, 2024.

Stakeholder Impact

• Shareholders are impacted by the net loss, reduced dividend, and debt rating downgrades.
• Employees may be affected by the store closures and restructuring efforts.
• Customers may experience changes in store locations and services due to the optimization program.
• Suppliers may be impacted by changes in the company's procurement strategies.
• Creditors are impacted by the company's debt rating downgrades and increased financial risk.

Next Steps

• The company will continue to execute its Transformational Cost Management Program to achieve its cost savings target.
• The company will finalize a significant multi-year U.S. footprint optimization program to close certain underperforming stores.
• The company will launch a U.S. Retail Pharmacy action plan to invest in and deliver an improved customer and patient experience across channels.
• The company will align U.S. Pharmacy and Healthcare organizations for enhanced go-to-market capabilities.
• The company will simplify and focus the U.S. Healthcare portfolio, including the assessment of the company's investment in VillageMD.

Key Dates

Keywords

Walgreens Boots Alliance, WBA, pharmacy, healthcare, retail, goodwill impairment, opioid litigation, cost management, strategic review, VillageMD, Boots, Cencora, financial results